Eisai
Eisai Co., Ltd., commonly referred to as Eisai, is a global pharmaceutical company headquartered in Tokyo, Japan. Founded in 1941, Eisai has established a strong presence in key operational regions, including North America, Europe, and Asia, focusing on the development of innovative medicines. The company primarily operates within the pharmaceutical industry, with a particular emphasis on neurology and oncology. Eisai is renowned for its core products, including the Alzheimer's treatment Aricept and the anti-cancer agent Lenvima, both of which exemplify the company's commitment to addressing unmet medical needs. With a dedication to research and development, Eisai has achieved notable milestones, positioning itself as a leader in the pharmaceutical market. The company's unique approach to patient-centric healthcare continues to drive its success and reputation within the industry.
DitchCarbon Score
How does Eisai's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai's score of 23 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eisai's reported carbon emissions
Eisai has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets. By fiscal 2030, Eisai aims to reduce its Scope 1 and Scope 2 GHG emissions by 55% from a 2019 baseline. Additionally, the company plans to cut its Scope 3 emissions (Category 1) by 27.5% within the same timeframe. Eisai's long-term goal is to achieve Net-Zero emissions across all scopes by 2050. These commitments reflect the company's dedication to sustainability and its proactive approach to addressing climate change. Through these initiatives, Eisai is positioning itself as a responsible leader in the pharmaceutical industry, committed to reducing its environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eisai is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
